US pharmaceuticals firm Vertex is among the latest investors in Oxford biotech Genomics, helping raise £25m ($32m) and forming a collaboration that could lead to the further development of the genetics company. Founded in 2014, by billions of the UK's leading geneticists with the aim of using genetic information to improve drug development, Genomics utilises human genetic data collected from worldwide research studies to develop an improved method of understanding how human biology is affected by different drugs. Genomics’ CEO Professor Peter Donnelly said the firm is already engaged in discussions with pharmaceutical companies looking to follow Vertex.
US pharmaceuticals firm Vertex is among the latest investors in Oxford biotech Genomics, helping raise £25m ($32m) and forming a collaboration that could lead to the further development of the genetics company. Founded in 2014, by four of the UK's leading geneticists with the aim of using genetic information to improve drug development, Genomics utilises human genetic data collected from worldwide research studies to develop an improved method of understanding how human biology is affected by different drugs. Genomics’ CEO Professor Peter Donnelly said the firm is already engaged in discussions with pharmaceutical companies looking to follow Vertex.